CompletedPhase 2NCT00589563
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- City of Hope Medical Center
- Principal Investigator
- Ryotaro Nakamura, MDCity of Hope Comprehensive Cancer Center
- Intervention
- anti-thymocyte globulin(biological)
- Enrollment
- 32 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2007 – 2012
Study locations (2)
- Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00589563 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.